We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
-12.57%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$168M
AUM Growth
+$45.3M
Cap. Flow
+$93.3M
Cap. Flow %
55.55%
Top 10 Hldgs %
76.92%
Holding
27
New
11
Increased
8
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$68.1M
2
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$13.5M
3
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$13M
4
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$12.5M
5
VCYT icon
Veracyte
VCYT
+$7.26M

Top Sells

Rank Stock Value
1
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$29.2M
2
QLTI
QLT Inc
QLTI
+$11.9M
3
CUTR
Cutera, Inc.
CUTR
+$4.18M
4
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$458K
5
VXRT
Vaxart
VXRT
+$53K

Sector Composition

Rank Sector Weight
1 Healthcare 89.73%
2 Miscellaneous 10.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCTL
1
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$23.2M 13.8%
3,204,863
+1,899,644
+146% +$13M
ALR
2
DELISTED
Alere Inc
ALR
$14M 8.36%
360,000
+73,349
+26% +$2.97M
SCLN
3
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$13.5M 8.04%
+1,249,200
New +$12.5M
VIVE
4
DELISTED
VIVEVE MED INC
VIVE
$13.3M 7.92%
2,600
– –
NVLN
5
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$12.8M 7.64%
+1,524,034
New +$13.5M
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$11.1M 6.6%
+2,292,900
New +$68.1M
CORV
7
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$8.72M 5.19%
3,158,816
+1,240,094
+65% +$3.55M
ENTA icon
8
Enanta Pharmaceuticals
ENTA
$408M
$7.77M 4.63%
+231,913
New +$6.65M
VCYT icon
9
Veracyte
VCYT
$3.59B
$7.51M 4.47%
+970,500
New +$7.26M
VCEL icon
10
Vericel Corp
VCEL
$2.07B
$5.65M 3.37%
1,883,800
+860,752
+84% +$2.21M
ALIM
11
DELISTED
Alimera Sciences
ALIM
$4.99M 2.97%
307,721
+180,575
+142% +$3.31M
BDSI
12
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.55M 2.71%
+2,600,711
New +$5.31M
SCMP
13
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$3.85M 2.29%
+284,002
New +$3.96M
CPIX icon
14
Cumberland Pharmaceuticals
CPIX
$101M
$3.41M 2.03%
619,538
+295,791
+91% +$1.54M
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
$3.39M 2.02%
+326,087
New +$3.58M
TRIB
16
Trinity Biotech
TRIB
$7.81M
$3.02M 1.8%
+2,907
New +$3M
DRRX
17
DELISTED
DURECT Corp
DRRX
$2.92M 1.74%
217,779
+53,162
+32% +$679K
MNK
18
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$2.17M 1.29%
+43,629
New +$2.57M
CUTR
19
DELISTED
Cutera, Inc.
CUTR
$2.09M 1.24%
120,429
-279,571
-70% -$4.18M
JNP
20
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$1.28M 0.76%
228,392
+54,425
+31% +$299K
CTIC
21
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.07M 0.64%
+261,714
New +$1.09M
VXRT
22
DELISTED
Vaxart
VXRT
$380K 0.23%
28,116
-3,469
-11% -$53K
PCRX icon
23
Pacira BioSciences
PCRX
$1.06B
– –
-1,500
Closed -$51K
QLTI
24
DELISTED
QLT Inc
QLTI
– –
-5,778,496
Closed -$11.9M
TBRA
25
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-733,718
Closed -$29.2M
1
2

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Stonepine Capital Management held 27 positions worth $168M, up 37% from $123M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Stonepine Capital Management deployed $93.3M of net new capital in Q4 2016, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was IVERIC bio, Inc. Common Stock: 2,292,900 shares worth $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Cutera, Inc., an estimated $4.18M trimmed.

  • Stonepine Capital Management's largest Q4 2016 buy was IVERIC bio, Inc. Common Stock: 2,292,900 shares worth $11.1M.
  • Stonepine Capital Management added most to Societal CDMO, Inc. Common Stock in Q4 2016, an estimated $13M increase.
  • Stonepine Capital Management's biggest Q4 2016 reduction was Cutera, Inc., cutting an estimated $4.18M.
  • Stonepine Capital Management fully exited Tobira Therapeutics, Inc. Common Stock in Q4 2016, selling an estimated $29.2M.
  • Stonepine Capital Management's ten largest holdings make up 77% of its $168M portfolio in Q4 2016.
  • Stonepine Capital Management opened 11 new positions and closed 4 in Q4 2016.
  • Stonepine Capital Management's portfolio value rose 37% quarter-over-quarter to $168M.

Based on Stonepine Capital Management's 13F filing for Q4 2016, filed 10 Feb 2017.